Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: India Globalization Capital, Inc.

Market Cap 26.34M 23.02M 21.29M 19.87M 37.3M 2.49B 37.58M 253M 98.43M 1.22B 98.89M 96.75M 4.25B P/E 2026 *
-2.96x
P/E 2027 * -3.33x
Enterprise Value 26.34M 23.02M 21.29M 19.87M 37.3M 2.49B 37.58M 253M 98.43M 1.22B 98.89M 96.75M 4.25B EV / Sales 2026 *
30.7x
EV / Sales 2027 * 25.6x
Free-Float
90.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 28/04/2005
Director of Finance/CFO 55 08/05/2018
Chief Operating Officer - 31/07/2019
Director TitleAgeSince
Chairman 67 28/04/2005
Director/Board Member 55 22/03/2022
Chairman 69 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
-79.71%-47.69% - - 26.34M
+3.46%+4.57%-7.84%-2.42% 43.24B
+1.66%+6.12%+314.97%+551.08% 35.25B
+0.75%+3.73%+6.31%+52.70% 30.22B
+0.88%-5.10%+9.58%-20.56% 28.01B
-1.06%-3.71%+9.08%+19.56% 24.08B
+1.75%-1.16% - - 14.16B
+0.90%-0.24%+49.20%+106.14% 13.01B
+2.68%+3.92%+9.51%+15.20% 12.7B
+0.60%+4.45%+102.67%+92.60% 12.54B
Average +15.41%-0.27%+61.68%+101.79% 23.69B
Weighted average by Cap. +1.42%-0.20%+67.77%+118.29%

Financials

2026 *2027 *
Net sales 857K 749K 693K 647K 1.21M 80.99M 1.22M 8.23M 3.2M 39.82M 3.22M 3.15M 138M 1.03M 899K 831K 776K 1.46M 97.19M 1.47M 9.88M 3.84M 47.79M 3.86M 3.78M 166M
Net income -8.78M -7.67M -7.1M -6.62M -12.44M -830M -12.53M -84.34M -32.82M -408M -32.97M -32.25M -1.42B -4.21M -3.68M -3.4M -3.18M -5.97M -398M -6.01M -40.46M -15.74M -196M -15.81M -15.47M -680M
Net Debt - -
Logo India Globalization Capital, Inc.
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!